Global Journal of Medical Research, A: Neurology & Nervous System, Volume 23 Issue 3

Table 1: Descriptive statistics and prevalences of altered instruments and inflammation markers (blood count = CBC) Variables Mean ± DP ou Median (P25 – P75) n (%) LSAS 54 (26,8 – 86,0) ≥ 32 points 59 (72,0) GAD-7 7 (3 – 11) ≥ 5 points 55 (67,1) BPRS 21,5 (13 – 30,3) ≥ 5 points 78 (95,1) BLOOD COUNT Neutrophils 4,98 ± 2,05 Monocytes 0,59 ± 0,21 Lymphocytes 2,05 ± 0,76 Platelets 215,4 ± 65,5 Neutrophil-lymphocyteratio 2,50 (1,50 – 3,49) ≥ 2,80 35 (42,7) Monocyte-lymphocyteratio 0,29 (0,22 – 0,37) ≥ 0,35 25 (30,5) Platelet-lymphocyteratio 108,1 (82,8 – 143,5) ≥ 362 0 (0,0) Systemicimmune-inflammatory index 535 (303,5 – 794,2) ≥ 761 21 (25,6) Table 2: Correlation between the LSAS, GAD-7 and BPRS scales with the inflammation markers NLR, SII, MLR and PLR, through Spearman's correlation coefficient. LSAS = Liebowitz Social Anxiety Scale; BRPS = Brief Psychiatric Rating Scale; GAD-7 = Generalized Anxiety Disorder Scale; NLR = Neutrophil-to-Lymphocyte Ratio; SII = Systemic Immune-Inflammatory Index; MLR = Monocyte-to-Lymphocyte Ratio; PLR = Platelet-to-Lymphocyte Ratio; rs = Spearman's correlation coefficient. Markers of Inflammation LSAS GAD-7 BPRS r s p r s p r s P NLR 0,241 0,029 0,020 0,860 -0,058 0,606 SII 0,257 0,020 0,111 0,321 -0,054 0,630 MLR 0,110 0,326 -0,005 0,963 -0,043 0,702 PLR 0,236 0,032 0,112 0,318 -0,003 0,982 Table 3: Prevalence of alterations in the GAD-7 and BPRS scales and in the blood count according to the LSAS classification Variables No AS (n=23; 28%) Yes AS (n=59; 72%) P GAD-7 ≥ 5 points 9 (39,1) 46 (78,0) 0,002 BPRS ≥ 5 points 19 (82,6) 59 (100) 0,005 BLOOD COUNT Neutrophil-lymphocyteratio ≥ 2,80 5 (21,7) 30 (50,8) 0,032 Monocyte-lymphocyteratio ≥ 0,35 4 (17,4) 21 (35,6) 0,180 Systemicimmune-inflammatory index ≥ 761 3 (13,0) 18 (30,5) 0,178 41 Year 2023 Global Journal of Medical Research Volume XXIII Issue III Version I ( D ) A © 2023 Global Journals The Link between Social Anxiety and Peripheral Inflammatory Markers in Patients with Schizophrenia Diagnoses